The goal of this type of clinical trial study is to evaluate the safety and efficacy of Surufatinib combined with Carboplatin/Paclitaxel and Surufatinib combined with Olaparib as first-line and maintenance therapy for newly diagnosed high-risk ovarian cancer
Age: 18-75 years old (≥18, ≤75)
FIGO stage III with non-R0 resection;
FIGO stage IV;
Presence of ascites at initial diagnosis.
Previous treatment with anti-angiogenic drugs such as apatinib, sorafenib, anlotinib, bevacizumab, or other anti-angiogenic therapies.
Pregnant or breastfeeding women.
Patients who have previously participated in other clinical trials that have not yet concluded.
Patients with evidence or history of significant bleeding tendencies or events within 3 months before enrollment (bleeding >30 mL, accompanied by hematemesis, melena, or hematochezia), hemoptysis (≥5 mL of fresh blood within 4 weeks), or thromboembolic events (including stroke and/or transient ischemic attack) within 12 months.
Anhui Provincial Cancer Hospital
Lead sponsor
Hutchison Medipharma Limited
Collaborator